Holen Sie sich die Stockscreener-App
247.79
3.34%
8.01
Handel nachbörslich:
247.79
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$239.78
Offen:
$244.54
24-Stunden-Volumen:
961.35K
Relative Volume:
1.15
Marktkapitalisierung:
$36.40B
Einnahmen:
$4.81B
Nettoeinkommen (Verlust:
$1.11B
KGV:
32.82
EPS:
7.55
Netto-Cashflow:
$1.35B
1W Leistung:
+8.29%
1M Leistung:
+4.43%
6M Leistung:
+21.97%
1J Leistung:
+43.61%
1-Tages-Spanne:
$243.88
$249.31
1-Wochen-Bereich:
$229.09
$249.31
52-Wochen-Spanne:
$170.56
$260.49
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
247.79 | 36.40B | 4.81B | 1.11B | 1.35B | 7.55 |
|
ISRG
Intuitive Surgical Inc
|
604.12 | 215.18B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
240.37 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
88.54 | 43.79B | 9.76B | 1.16B | 665.00M | 2.34 |
|
WST
West Pharmaceutical Services Inc
|
344.69 | 25.00B | 2.88B | 499.60M | 321.60M | 6.74 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
Should you buy CSL and ResMed shares in January? - The Motley Fool Australia
ResMed Inc (RMD) Stock Price Up 3.18% on Jan 21 - GuruFocus.com
ResMed Inc. (NYSE:RMD) Shares Sold by Addenda Capital Inc. - MarketBeat
Park Avenue Securities LLC Has $1.01 Million Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
Ritholtz Wealth Management Cuts Position in ResMed Inc. (NYSE:RMD) - MarketBeat
ChartWatch ASX Scans: Pointerra, Cyclone Metals, Ingenia Communities, Macquarie Group, Resmed, Audinate, Dicker Data, Weebit Nano - MSN
Assistive Technology Market Set to Witness Significant Growth by 2025-2032: Sunrise Medical LLC., Tobii AB, - EIN News
Assenagon Asset Management S.A. Sells 14,445 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. (NYSE:RMD) Shares Sold by Assenagon Asset Management S.A. - Defense World
ResMed Gains 37.8% in a Year: What's Driving the Stock? - MSN
Integrated Investment Consultants LLC Makes New Investment in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed (NYSE:RMD) Research Coverage Started at The Goldman Sachs Group - Defense World
1,453 Shares in ResMed Inc. (NYSE:RMD) Bought by Occidental Asset Management LLC - MarketBeat
Goldman Sachs tips ResMed shares to rocket 30% to a record high - MSN
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Goldman Sachs starts coverage on ResMed with "buy" rating - MSN
The Goldman Sachs Group Begins Coverage on ResMed (NYSE:RMD) - MarketBeat
ASX Broker Moves: Upgrades for Baby Bunting, Resmed vs Downgrades for Computershare, Monadelphous, Beach Energy - MSN
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Peak Financial Advisors LLC Invests $2.97 Million in ResMed Inc. (NYSE:RMD) - MarketBeat
Board of the Pension Protection Fund Makes New $915,000 Investment in ResMed Inc. (NYSE:RMD) - MarketBeat
The Zacks Analyst Blog Highlights Vertiv, Goldman Sachs, ResMed, Ralph Lauren and Amazon - Yahoo Finance
Czech National Bank Raises Stock Position in ResMed Inc. (NYSE:RMD) - Defense World
ResMed shares are up 42% in a year. This shows why they could still be great value - MSN
ResMed shares are in a two-month lull. Is this a chance to buy? - MSN
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Respiratory Devices Market Set to Witness Significant Growth by 2024-2031 | Medtronic, Hamilton Medical, - EIN News
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Zacks.com featured highlights Chipotle Mexican Grill, ResMed and ServiceNow - Yahoo Finance
ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan - TipRanks
Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus.com
Piper Sandler Initiates Coverage on ResMed (NYSE:RMD) - Defense World
Is There An Opportunity With ResMed Inc.'s (NYSE:RMD) 31% Undervaluation? - Yahoo Finance
Piper Sandler Initiates Coverage of ResMed (RMD) with Neutral Recommendation - MSN
ResMed CFO Brett Sandercock sells shares worth $234,040 By Investing.com - Investing.com Australia
ResMed CFO Brett Sandercock sells shares worth $234,040 - Investing.com India
ResMed Inc. stock outperforms market despite losses on the day - MarketWatch
Piper Sandler Begins Coverage on ResMed (NYSE:RMD) - MarketBeat
Piper Sandler starts ResMed stock at Neutral, says execution rock solid By Investing.com - Investing.com South Africa
Piper Sandler starts ResMed stock at Neutral, says execution rock solid - Investing.com India
What 5 Analyst Ratings Have To Say About ResMed - Benzinga
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025 - GlobeNewswire
Sleep Study Equipment Market Seeking Excellent Growth | ResMed, - openPR
ResMed Inc. (NYSE:RMD) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
ResMed Inc. (NYSE:RMD) Given Average Recommendation of “Hold” by Brokerages - Defense World
Resmed Inc Officer Plans Further Sale of Common Shares - TipRanks
ResMed (RMD) is an Incredible Growth Stock: 3 Reasons Why - MSN
Here's Why ResMed (RMD) is a Strong Growth Stock - MSN
Birch Capital Management LLC Raises Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
Nordea Investment Management AB Acquires 215,561 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):